Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Published:2014-10-23 Issue:17 Volume:371 Page:1609-1618
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Loupakis Fotios,Cremolini Chiara,Masi Gianluca,Lonardi Sara,Zagonel Vittorina,Salvatore Lisa,Cortesi Enrico,Tomasello Gianluca,Ronzoni Monica,Spadi Rosella,Zaniboni Alberto,Tonini Giuseppe,Buonadonna Angela,Amoroso Domenico,Chiara Silvana,Carlomagno Chiara,Boni Corrado,Allegrini Giacomo,Boni Luca,Falcone Alfredo

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1403108

Cited by 865 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAS mutation associated with short surgically controllable period in colorectal liver metastases: a retrospective study;World Journal of Surgical Oncology;2024-09-12

2. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib;The Oncologist;2024-09-07

3. Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study;Digestive and Liver Disease;2024-09

4. PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial;European Journal of Surgical Oncology;2024-09

5. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC;Med;2024-09